CML Buys ChemShop

Cambridge Major Laboratories Inc., a Germantown, Wis.-based provider of chemistry outsourcing to the pharma and biotech industries, has acquired ChemShop BV, a Dutch supplier of active pharmaceutical ingredient development services. No financial terms were disclosed. CML is owned by Arlington Capital Partners.

PRESS RELEASE
Arlington Capital Partners (www.arlingtoncap.com), a Washington, DC based private equity firm, today announced the acquisition of ChemShop B.V. by Arlington's portfolio company Cambridge Major Laboratories, Inc. (“CML”).

Cambridge Major Laboratories, Arlington's flagship investment within the outsourced pharmaceutical manufacturing and related support services industries, acquired ChemShop B.V., Weert Netherlands, a European supplier of Active Pharmaceutical Ingredient (API) development services. The newly combined company is one of the largest pharmaceutical chemistry development organizations in the western hemisphere, with over 140 employees operating at three facilities in the US and Europe.

“Arlington is excited to invest in the acquisition of ChemShop by CML. CML is a premier US based provider of outsourced chemistry services and ChemShop similarly has built an impeccable reputation as a provider of these services in Europe over the past decade. A merger of these well regarded firms creates an elite global company focusing exclusively on producing complex APIs ranging from a single gram to hundreds of kilograms” said Peter Manos, a Partner at Arlington Capital Partners.

Matt Altman of Arlington Capital Partners noted: “The addition of ChemShop with its strategic European location and customer relationships, positions CML as a global operation servicing the bulk of the world's pharmaceutical and biotech companies who reside in the western hemisphere. Arlington and CML are committed to pursuing additional opportunities to grow the combined business both organically and through future acquisitions.”

All of ChemShop's management and personnel will continue to operate the business at the Netherlands facility which includes R&D laboratories, GMP kilo lab suites, and a GMP pilot plant. CML will fund the expansion of the European site which will include more reactor capacity, laboratories, and expansion of the company's high potency API (“HPAPI”) manufacturing capabilities to keep the ChemShop site on a fast growth track. The planned expansion will commence immediately and be completed in the second half of 2008.

“The addition of ChemShop presents an enormous opportunity for both companies to further tap into the growing European pharmaceutical market and to penetrate deeper into the US market as we leverage our combined technical expertise and human resources.” said Michael W. Major, President and CEO, Cambridge Major Laboratories. “More importantly, both organizations share the same mentality and business approach which will further bolster CML's technological reputation and expand its global capabilities in API-related chemistry services.”

“We are exited to serve the industry together with CML and we are convinced that the combined expertise will create a unique company able to provide even better performance than before,” said Peter Van Tilburg, CEO, ChemShop BV. “The synergies between both companies are truly fantastic and will without any doubt result in a huge added value for our customers.”

About Arlington Capital Partners:

Arlington Capital Partners is a Washington, DC based private equity fund with over $1 billion of committed capital focused on middle market buyout investment opportunities in growth industries including: media and information services, healthcare services, aerospace/defense, business services and outsourcing, and education. The firm's professionals have a unique combination of operating and private equity experience that enables Arlington to be a value-added investor. Arlington invests in companies in partnership with high quality management teams that are motivated to establish and/or advance their company's position as leading competitors in their field.

www.arlingtoncap.com

SOURCE: Arlington Capital Partners

Contact:

Peter Manos or Matt Altman
Arlington Capital Partners
600 New Hampshire Ave., NW
Suite 660

Washington, DC 20037

Phone: (202) 337-7500
Fax: (202) 337-7525
Email: arlington_capital@arlingtoncap.com

About Cambridge Major Laboratories:

Cambridge Major Laboratories, Inc. is a leading global service-based chemistry outsourcing partner to the pharmaceutical and biotechnology industries, producing pharmaceutical intermediates, Active Pharmaceutical Ingredients, and other fine organic chemicals. The Company specializes in chemical process development and advanced multi-step organic synthesis, and operates out of three facilities in the US and Europe. The Company has been FDA inspected and approved for cGMP manufacturing. Visit us at www.c-mlabs.com